{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:35:44Z","timestamp":1773189344210,"version":"3.50.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2015,9,9]],"date-time":"2015-09-09T00:00:00Z","timestamp":1441756800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2015,9,9]],"date-time":"2015-09-09T00:00:00Z","timestamp":1441756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1038\/leu.2015.242","type":"journal-article","created":{"date-parts":[[2015,9,9]],"date-time":"2015-09-09T06:45:56Z","timestamp":1441781156000},"page":"464-472","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Target interaction profiling of midostaurin and its metabolites in neoplastic mast cells predicts distinct effects on activation and growth"],"prefix":"10.1038","volume":"30","author":[{"given":"B","family":"Peter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G E","family":"Winter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Blatt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K L","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Stefanzl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U","family":"Rix","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Eisenwort","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7409-4204","authenticated-orcid":false,"given":"E","family":"Hadzijusufovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Gridling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Dutreix","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Hoermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Schwaab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Radia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Roesel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P W","family":"Manley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Reiter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Superti-Furga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Valent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,9,9]]},"reference":[{"key":"BFleu2015242_CR1","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1046\/j.1365-2141.2003.04575.x","volume":"122","author":"P Valent","year":"2003","unstructured":"Valent P, Akin C, Sperr WR, Horny HP, Arock M, Lechner K et al. Diagnosis and treatment of systemic mastocytosis: state of the art. Br J Haematol 2003; 122: 695\u2013717.","journal-title":"Br J Haematol"},{"key":"BFleu2015242_CR2","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1146\/annurev.med.55.091902.103822","volume":"55","author":"C Akin","year":"2004","unstructured":"Akin C, Metcalfe DD . Systemic mastocytosis. Annu Rev Med 2004; 55: 419\u2013432.","journal-title":"Annu Rev Med"},{"key":"BFleu2015242_CR3","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1586\/ehm.10.42","volume":"3","author":"M Arock","year":"2010","unstructured":"Arock M, Valent P . Pathogenesis, classification and treatment of mastocytosis: state of the art in 2010 and future perspectives. Expert Rev Hematol 2010; 3: 497\u2013516.","journal-title":"Expert Rev Hematol"},{"key":"BFleu2015242_CR4","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/S0145-2126(01)00021-2","volume":"25","author":"HP Horny","year":"2001","unstructured":"Horny HP, Valent P . Diagnosis of mastocytosis: general histopathological aspects, morphological criteria, and immunohistochemical findings. Leuk Res 2001; 25: 543\u2013551.","journal-title":"Leuk Res"},{"key":"BFleu2015242_CR5","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1159\/000101711","volume":"74","author":"HP Horny","year":"2007","unstructured":"Horny HP, Sotlar K, Valent P . Mastocytosis: state of the art. Pathobiology 2007; 74: 121\u2013132.","journal-title":"Pathobiology"},{"key":"BFleu2015242_CR6","doi-asserted-by":"publisher","first-page":"10560","DOI":"10.1073\/pnas.92.23.10560","volume":"92","author":"H Nagata","year":"1995","unstructured":"Nagata H, Worobec AS, Oh CK, Chowdhury BA, Tannenbaum S, Suzuki Y et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci USA 1995; 92: 10560\u201310564.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFleu2015242_CR7","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/ng0396-312","volume":"12","author":"BJ Longley","year":"1996","unstructured":"Longley BJ, Tyrrell L, Lu SZ, Ma YS, Langley K, Ding TG et al. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. Nat Genet 1996; 12: 312\u2013314.","journal-title":"Nat Genet"},{"key":"BFleu2015242_CR8","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1073\/pnas.96.4.1609","volume":"96","author":"BJ Longley","year":"1999","unstructured":"Longley BJ, Metcalfe DD, Tharp M, Wang X, Tyrrell L, Lu SZ et al. Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. Proc Natl Acad Sci USA 1999; 96: 1609\u20131614.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFleu2015242_CR9","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1046\/j.1365-2141.2001.02783.x","volume":"113","author":"R Fritsche-Polanz","year":"2001","unstructured":"Fritsche-Polanz R, Jordan JH, Feix A, Sperr WR, Sunder-Plassmann G, Valent P et al. Mutation analysis of C-KIT in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis. Br J Haematol 2001; 113: 357\u2013364.","journal-title":"Br J Haematol"},{"key":"BFleu2015242_CR10","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1159\/000048179","volume":"127","author":"F F\u00e9ger","year":"2002","unstructured":"F\u00e9ger F, Ribadeau Dumas A, Leriche L, Valent P, Arock M . Kit and c-kit mutations in mastocytosis: a short overview with special reference to novel molecular and diagnostic concepts. Int Arch Allergy Immunol 2002; 127: 110\u2013114.","journal-title":"Int Arch Allergy Immunol"},{"key":"BFleu2015242_CR11","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/S0145-2126(02)00168-6","volume":"27","author":"P Valent","year":"2003","unstructured":"Valent P, Akin C, Sperr WR, Escribano L, Arock M, Horny HP et al. Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria. Leuk Res 2003; 27: 635\u2013641.","journal-title":"Leuk Res"},{"key":"BFleu2015242_CR12","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s00277-002-0575-z","volume":"81","author":"L Escribano","year":"2002","unstructured":"Escribano L, Akin C, Castells M, Orfao A, Metcalfe DD . Mastocytosis: current concepts in diagnosis and treatment. Ann Hematol 2002; 81: 677\u2013690.","journal-title":"Ann Hematol"},{"key":"BFleu2015242_CR13","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1111\/j.1365-2362.2007.01807.x","volume":"37","author":"P Valent","year":"2007","unstructured":"Valent P, Akin C, Escribano L, F\u00f6dinger M, Hartmann K, Brockow K et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest 2007; 37: 435\u2013453.","journal-title":"Eur J Clin Invest"},{"key":"BFleu2015242_CR14","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1111\/j.1398-9995.2007.01569.x","volume":"63","author":"K Brockow","year":"2008","unstructured":"Brockow K, Jofer C, Behrendt H, Ring J . Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients. Allergy 2008; 63: 226\u2013232.","journal-title":"Allergy"},{"key":"BFleu2015242_CR15","doi-asserted-by":"publisher","first-page":"637","DOI":"10.2217\/imt.11.44","volume":"3","author":"D Gonz\u00e1lez-de-Olano","year":"2011","unstructured":"Gonz\u00e1lez-de-Olano D, Alvarez-Twose I, Vega A, Orfao A, Escribano L . Venom immunotherapy in patients with mastocytosis and hymenoptera venom anaphylaxis. Immunotherapy 2011; 3: 637\u2013651.","journal-title":"Immunotherapy"},{"key":"BFleu2015242_CR16","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1016\/j.jaci.2007.03.032","volume":"119","author":"MC Carter","year":"2007","unstructured":"Carter MC, Robyn JA, Bressler PB, Walker JC, Shapiro GG, Metcalfe DD . Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis. J Allergy Clin Immunol 2007; 119: 1550\u20131551.","journal-title":"J Allergy Clin Immunol"},{"key":"BFleu2015242_CR17","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jaci.2004.02.045","volume":"114","author":"P Valent","year":"2004","unstructured":"Valent P, Sperr WR, Schwartz LB, Horny HP . Diagnosis and classification of mast cell proliferative disorders: delineation from immunologic diseases and non-mast cell hematopoietic neoplasms. J Allergy Clin Immunol 2004; 114: 3\u201311.","journal-title":"J Allergy Clin Immunol"},{"key":"BFleu2015242_CR18","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3324\/haematol.12324","volume":"93","author":"A Tefferi","year":"2008","unstructured":"Tefferi A, Verstovsek S, Pardanani A . How we diagnose and treat WHO-defined systemic mastocytosis in adults. Haematologica 2008; 93: 6\u20139.","journal-title":"Haematologica"},{"key":"BFleu2015242_CR19","doi-asserted-by":"publisher","first-page":"5812","DOI":"10.1182\/blood-2010-08-292144","volume":"116","author":"P Valent","year":"2010","unstructured":"Valent P, Sperr WR, Akin C . How I treat patients with advanced systemic mastocytosis. Blood 2010; 116: 5812\u20135817.","journal-title":"Blood"},{"key":"BFleu2015242_CR20","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.1182\/blood-2005-04-1568","volume":"106","author":"J Gotlib","year":"2005","unstructured":"Gotlib J, Berub\u00e9 C, Growney JD, Chen CC, George TI, Williams C et al. Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Blood 2005; 106: 2865\u20132870.","journal-title":"Blood"},{"key":"BFleu2015242_CR21","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1182\/blood-2005-07-3022","volume":"107","author":"KV Gleixner","year":"2006","unstructured":"Gleixner KV, Mayerhofer M, Aichberger KJ, Derdak S, Sonneck K, B\u00f6hm A et al. PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects. Blood 2006; 107: 752\u2013759.","journal-title":"Blood"},{"key":"BFleu2015242_CR22","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1182\/blood-2005-10-3969","volume":"108","author":"NP Shah","year":"2006","unstructured":"Shah NP, Lee FY, Luo R, Jiang Y, Donker M, Akin C . Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. Blood 2006; 108: 286\u2013291.","journal-title":"Blood"},{"key":"BFleu2015242_CR23","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.3324\/haematol.11339","volume":"92","author":"KV Gleixner","year":"2007","unstructured":"Gleixner KV, Mayerhofer M, Sonneck K, Gruze A, Samorapoompichit P, Baumgartner C et al. Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT. Haematologica 2007; 92: 1451\u20131459.","journal-title":"Haematologica"},{"key":"BFleu2015242_CR24","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1182\/blood.V120.21.799.799","volume":"120","author":"J Gotlib","year":"2012","unstructured":"Gotlib J, Kluin-Nelemans HC, George TI, Akin C, Sotlar K, Hermine O et al. KIT inhibitor midostaurin in patients with advanced systemic mastocytosis: results of a planned interim analysis of the global CPKC412D2201 trial. Blood 2012; 120: 799.","journal-title":"Blood"},{"key":"BFleu2015242_CR25","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/j.leukres.2011.05.006","volume":"35","author":"C Ustun","year":"2011","unstructured":"Ustun C, DeRemer DL, Akin C . Tyrosine kinase inhibitors in the treatment of systemic mastocytosis. Leuk Res 2011; 35: 1143\u20131152.","journal-title":"Leuk Res"},{"key":"BFleu2015242_CR26","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/S0301-472X(03)00112-7","volume":"31","author":"C Akin","year":"2003","unstructured":"Akin C, Brockow K, D'Ambrosio C, Kirshenbaum AS, Ma Y, Longley BJ et al. Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit. Exp Hematol 2003; 31: 686\u2013692.","journal-title":"Exp Hematol"},{"key":"BFleu2015242_CR27","first-page":"17","volume":"15","author":"D Fabbro","year":"2000","unstructured":"Fabbro D, Ruetz S, Bodis S, Pruschy M, Csermak K, Man A et al. PKC412 - a protein kinase inhibitor with a broad therapeutic potential. Anticancer Drug Des 2000; 15: 17\u201328.","journal-title":"Anticancer Drug Des"},{"key":"BFleu2015242_CR28","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1182\/blood-2004-12-4617","volume":"106","author":"JD Growney","year":"2005","unstructured":"Growney JD, Clark JJ, Adelsperger J, Stone R, Fabbro D, Griffin JD, Gilliland DG . Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412. Blood 2005; 106: 721\u2013724.","journal-title":"Blood"},{"key":"BFleu2015242_CR29","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/nbt1358","volume":"26","author":"MW Karaman","year":"2008","unstructured":"Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, Campbell BT et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 2008; 26: 127\u2013132.","journal-title":"Nat Biotechnol"},{"key":"BFleu2015242_CR30","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1182\/blood-2013-05-500959","volume":"122","author":"J Gotlib","year":"2013","unstructured":"Gotlib J, Kluin-Nelemans HC, George TI, Akin C, Sotlar K, Hermine O et al. Durable responses and improved quality of life with midostaurin (PKC412) in advanced systemic mastocytosis (SM): updated stage 1 results of the global D2201 trial. Blood 2013; 122: 106.","journal-title":"Blood"},{"key":"BFleu2015242_CR31","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.1182\/blood-2007-08-104372","volume":"111","author":"M Kneidinger","year":"2008","unstructured":"Kneidinger M, Schmidt U, Rix U, Gleixner KV, Vales A, Baumgartner C et al. The effects of dasatinib on IgE receptor-dependent activation and histamine release in human basophils. Blood 2008; 111: 3097\u20133107.","journal-title":"Blood"},{"key":"BFleu2015242_CR32","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1111\/j.1365-2222.2009.03353.x","volume":"39","author":"MT Krauth","year":"2009","unstructured":"Krauth MT, Mirkina I, Herrmann H, Baumgartner C, Kneidinger M, Valent P . Midostaurin (PKC412) inhibits immunoglobulin E-dependent activation and mediator release in human blood basophils and mast cells. Clin Exp Allergy 2009; 39: 1711\u20131720.","journal-title":"Clin Exp Allergy"},{"key":"BFleu2015242_CR33","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1200\/JCO.2001.19.5.1485","volume":"19","author":"DJ Propper","year":"2001","unstructured":"Propper DJ, McDonald AC, Man A, Thavasu P, Balkwill F, Braybrooke JP et al. Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C. J. Clin Oncol 2001; 19: 1485\u20131492.","journal-title":"Clin Oncol"},{"key":"BFleu2015242_CR34","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1182\/blood-2004-03-0891","volume":"105","author":"RM Stone","year":"2005","unstructured":"Stone RM, DeAngelo DJ, Klimek V, Galinsky I, Estey E, Nimer SD et al. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood 2005; 105: 54\u201360.","journal-title":"Blood"},{"key":"BFleu2015242_CR35","doi-asserted-by":"publisher","first-page":"3477","DOI":"10.1182\/blood-2006-04-015743","volume":"108","author":"M Levis","year":"2006","unstructured":"Levis M, Brown P, Smith BD, Stine A, Pham R, Stone R et al. Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors. Blood 2006; 108: 3477\u20133483.","journal-title":"Blood"},{"key":"BFleu2015242_CR36","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1007\/s00280-013-2287-6","volume":"72","author":"C Dutreix","year":"2013","unstructured":"Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y . Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers. Cancer Chemother Pharmacol 2013; 72: 1223\u20131234.","journal-title":"Cancer Chemother Pharmacol"},{"key":"BFleu2015242_CR37","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1177\/0091270008318006","volume":"48","author":"Y Wang","year":"2008","unstructured":"Wang Y, Yin OQ, Graf P, Kisicki JC, Schran H . Dose- and time-dependent pharmacokinetics of midostaurin in patients with diabetes mellitus. J Clin Pharmacol 2008; 48: 763\u2013775.","journal-title":"J Clin Pharmacol"},{"key":"BFleu2015242_CR38","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1182\/blood.V73.7.1778.1778","volume":"73","author":"P Valent","year":"1989","unstructured":"Valent P, Ashman LK, Hinterberger W, Eckersberger F, Majdic O, Lechner K et al. Mast cell typing: demonstration of a distinct hematopoietic cell type and evidence for immunophenotypic relationship to mononuclear phagocytes. Blood 1989; 73: 1778\u20131785.","journal-title":"Blood"},{"key":"BFleu2015242_CR39","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1189\/jlb.1112609","volume":"95","author":"B Peter","year":"2014","unstructured":"Peter B, Cerny-Reiterer S, Hadzijusufovic E, Schuch K, Stefanzl G, Eisenwort G et al. The pan-Bcl-2 blocker obatoclax promotes the expression of Puma, Noxa, and Bim mRNA and induces apoptosis in neoplastic mast cells. J Leukoc Biol 2014; 95: 95\u2013104.","journal-title":"J Leukoc Biol"},{"key":"BFleu2015242_CR40","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/0145-2126(88)90050-1","volume":"12","author":"JH Butterfield","year":"1988","unstructured":"Butterfield JH, Weiler D, Dewald G, Gleich GJ . Establishment of an immature mast cell line from a patient with mast cell leukemia. Leuk Res 1988; 12: 345\u2013355.","journal-title":"Leuk Res"},{"key":"BFleu2015242_CR41","doi-asserted-by":"publisher","first-page":"4055","DOI":"10.1182\/blood-2007-07-102061","volume":"110","author":"U Rix","year":"2007","unstructured":"Rix U, Hantschel O, D\u00fcrnberger G, Remsing Rix LL, Planyavsky M, Fernbach NV et al. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood 2007; 110: 4055\u20134063.","journal-title":"Blood"},{"key":"BFleu2015242_CR42","doi-asserted-by":"publisher","first-page":"13283","DOI":"10.1073\/pnas.0702654104","volume":"104","author":"O Hantschel","year":"2007","unstructured":"Hantschel O, Rix U, Schmidt U, B\u00fcrckst\u00fcmmer T, Kneidinger M, Sch\u00fctze G et al. The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. Proc Natl Acad Sci USA 2007; 104: 13283\u201313288.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFleu2015242_CR43","doi-asserted-by":"publisher","first-page":"4753","DOI":"10.1021\/pr900455x","volume":"8","author":"NV Fernbach","year":"2009","unstructured":"Fernbach NV, Planyavsky M, M\u00fcller A, Breitwieser FP, Colinge J, Rix U et al. Acid elution and one-dimensional shotgun analysis on an Orbitrap mass spectrometer: an application to drug affinity chromatography. J Proteome Res 2009; 8: 4753\u20134765.","journal-title":"J Proteome Res"},{"key":"BFleu2015242_CR44","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jprot.2010.10.002","volume":"74","author":"KL Bennett","year":"2011","unstructured":"Bennett KL, Funk M, Tschernutter M, Breitwieser FP, Planyavsky M, Ubaida Mohien C et al. Proteomic analysis of human cataract aqueous humour: comparison of one-dimensional gel LCMS with two-dimensional LCMS of unlabelled and iTRAQ(R)-labelled specimens. J Proteomics 2011; 74: 151\u2013166.","journal-title":"J Proteomics"},{"key":"BFleu2015242_CR45","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1016\/j.ajpath.2011.01.020","volume":"178","author":"G Hoermann","year":"2011","unstructured":"Hoermann G, Cerny-Reiterer S, Pern\u00e9 A, Klauser M, Hoetzenecker K, Klein K et al. Identification of oncostatin M as a STAT5-dependent mediator of bone marrow remodeling in KIT D816V-positive systemic mastocytosis. Am J Pathol 2011; 178: 2344\u20132356.","journal-title":"Am J Pathol"},{"key":"BFleu2015242_CR46","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.exphem.2010.05.006","volume":"38","author":"A B\u00f6hm","year":"2010","unstructured":"B\u00f6hm A, Sonneck K, Gleixner KV, Schuch K, Pickl WF, Blatt K et al. In vitro and in vivo growth-inhibitory effects of cladribine on neoplastic mast cells exhibiting the imatinib-resistant KIT mutation D816V. Exp Hematol 2010; 38: 744\u2013755.","journal-title":"Exp Hematol"},{"key":"BFleu2015242_CR47","doi-asserted-by":"publisher","first-page":"2593","DOI":"10.1182\/blood-2007-02-076471","volume":"110","author":"E Voisset","year":"2007","unstructured":"Voisset E, Lopez S, Dubreuil P, De Sepulveda P . The tyrosine kinase FES is an essential effector of KITD816V proliferation signal. Blood 2007; 110: 2593\u20132599.","journal-title":"Blood"},{"key":"BFleu2015242_CR48","doi-asserted-by":"publisher","first-page":"4270","DOI":"10.1182\/blood-2003-05-1699","volume":"102","author":"HC Kluin-Nelemans","year":"2003","unstructured":"Kluin-Nelemans HC, Oldhoff JM, Van Doormaal JJ, Van 't Wout JW, Verhoef G, Gerrits WB et al. Cladribine therapy for systemic mastocytosis. Blood 2003; 102: 4270\u20134276.","journal-title":"Blood"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu2015242.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2015242","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2015242.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T16:08:03Z","timestamp":1648742883000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2015242"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,9]]},"references-count":48,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["BFleu2015242"],"URL":"https:\/\/doi.org\/10.1038\/leu.2015.242","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,9]]},"assertion":[{"value":"5 March 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2015","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2015","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2015","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"PV is a consultant in a global midostaurin trial sponsored by Novartis and received grant support and honoraria from Novartis. AR is a consultant in a global midostaurin trial sponsored by Novartis and received honoraria from Novartis. CD, JR and PWM are employed by Novartis Pharma AG. The remaining authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}